Sign in:
 Email
 Password  save:
  
 Company Reports 
 
 
Membership is free, please Sign Up.
  
My Recent Searches
  Help
  
   
 
 
Get Insiders for : 
Terns Pharmaceuticals, Inc. (TERN)  
$4.91 0.27 (5.82%) as of 4:30 Fri 4/26


Download
   
Exchange: N/A
Security Type: Common
Shares Out: 64,880,000
Market Cap: 318.56(M)
Last Volume: 0 Avg Vol: 0
52 Week Range: $3.37 - $13.15
Level I Sector: N/A
Level II Sector: N/A
Level III Sector: N/A

Member Indexes:
   

Rankings:
     
Insider 3 Months    :   -
Insider 6 Months    : 3.8
Insider 3/6 Months : 4.4
Guru Rank Number :  -
Guru Rank Value     :  -
Guru Occurances    :  -

 

            6 Months   1 Year   2 Year  
 
Company Profile   Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule single-agent and combination therapy candidates to address diseases, such as non-alcoholic steatohepatitis (NASH) and obesity. Co.'s primary program is TERN-101, a liver-distributed, non-bile acid Farnesoid X Receptor (FXR) agonist that has demonstrated sustained liver FXR activation, as well as a favorable tolerability profile across multiple clinical trials. Co.'s another clinical stage program, TERN-201, is an inhibitor of Vascular Adhesion Protein-1. Co. is also evaluating the potential to co-administer TERN-201 in combination with a metabolically active NASH treatment.

 
 
Summary  (Direct Transactions Only) 3 Months 6 Months 12 Months 24 Months
Total Shares Bought 0 1,486 23,591 14,909,528
Total Buy Value $0 $5,618 $36,787 $43,710,646
Total People Bought 0 2 3 7
Total Buy Transactions 0 2 5 24
Total Shares Sold 420,663 420,663 420,663 1,920,663
Total Sell Value $2,796,859 $2,796,859 $2,796,859 $11,046,859
Total People Sold 1 1 1 2
Total Sell Transactions 3 3 3 4
End Date 2024-01-28 2023-10-27 2023-04-28 2022-04-28

   
Records found: 44
  Page 1 of 2  
Filer's Name Relation Title Off-Dir-10% Tran. Date Form Action Price Mkt Value D/I Shares Holdings
Rank

  
3m +/-  
Form
   Vivo Capital Surplus Fund Viii, L.p. 10% Owner   –       –       •   2024-04-03 4 AS $6.20 $856,009 I/I (138,066) 268,573 -18%     
   Vivo Capital Surplus Fund Viii, L.p. 10% Owner   –       –       •   2024-04-02 4 AS $6.65 $674,842 I/I (101,480) 272,722 -26%     
   Vivo Capital Surplus Fund Viii, L.p. 10% Owner   –       –       •   2024-04-01 4 AS $6.99 $1,266,008 I/I (181,117) 275,772 -31%     
   Kuriakose Emil Chief Medical Officer   •       –      –    2024-03-10 3 IO $0.00 $0 D/D 0 58,750 -38%     
   Quigley Jill M. Sr. Advisor & Strategy Officer   •       •      –    2024-01-23 4 A $0.00 $0 D/D 15,000 30,000     -
   Quirk Erin President, Head of R&D   •       –      –    2024-01-23 4 A $0.00 $0 D/D 75,000 75,000     -
   Vignola Mark J. Chief Financial Officer   •       –      –    2024-01-23 4 A $0.00 $0 D/D 68,750 87,149     -
   Yoon Seokho Bryan COO and General Counsel   •       –      –    2024-01-23 4 A $0.00 $0 D/D 68,750 87,149     -
   Vignola Mark J. Chief Financial Officer   •       –      –    2023-11-30 4 B $3.78 $2,809 D/D 743 18,399 0.01 17%     
   Yoon Seokho Bryan COO and General Counsel   •       –      –    2023-11-30 4 B $3.78 $2,809 D/D 743 18,399 0.01 17%     
   Quigley Jill M. Sr. Advisor & Strategy Officer   •       •      –    2023-11-15 4 A $0.00 $0 D/D 15,000 15,000     -
   Yoon Seokho Bryan COO and General Counsel   •       –      –    2023-05-31 4 B $1.41 $14,096 D/D 9,997 17,656 0.01 -50%     
   Sundaram Senthil Vel Chief Executive Officer   •       •      –    2023-05-31 4 B $1.41 $2,977 D/D 2,111 9,770 0.01 -50%     
   Vignola Mark J. Chief Financial Officer   •       –      –    2023-05-31 4 B $1.41 $14,096 D/D 9,997 17,656 0.01 -50%     
   Gordon Carl L Director   –       •       •   2022-12-23 4 B $7.25 $1,000,000 I/I 137,931 4,882,854 2.25 51%     
   Orbimed Genesis Gp Llc Director   –       •       •   2022-12-23 4 B $7.25 $1,000,000 I/I 137,931 4,882,854 2.25 51%     
   Lu Hongbo   –       •      –    2022-12-23 4 B $7.25 $5,499,995 I/I 758,620 4,340,212 0.01 51%     
   Yoon Seokho Bryan COO and General Counsel   •       –      –    2022-11-30 4 B $1.41 $4 D/D 3 7,659 0.01 57%     
   Sundaram Senthil Vel Chief Executive Officer   •       •      –    2022-11-30 4 B $1.41 $4 D/D 3 7,659 0.01 57%     
   Vignola Mark J. Chief Financial Officer   •       –      –    2022-11-30 4 B $1.41 $4 D/D 3 7,659 0.01 57%     
   Oriental Spring Venture Ltd 10% Owner   –       –       •   2022-11-23 4 S $5.50 $8,250,000 I/I (1,500,000) 529,762 -97%     
   Vivo Capital Surplus Fund Viii, L.p. 10% Owner   –       –       •   2022-09-07 4 B $3.60 $2,160,000 I/I 600,000 3,581,592 1.5 120%     
   Lu Hongbo   –       •      –    2022-09-07 4 B $3.60 $2,160,000 I/I 600,000 3,581,592 0.01 120%     
   Gordon Carl L Director   –       •       •   2022-08-16 4 B $2.42 $8,929,800 I/I 3,690,000 762,400 2.25 84%     
   Orbimed Genesis Gp Llc Director   –       •       •   2022-08-16 4 B $2.42 $8,929,800 I/I 3,690,000 762,400 2.25 84%     
  44 Records found
  1  2   
  Page 1 of 2
  Transaction Code Key: Ownership Code Key
  B - Buy AB - Automatic Buy D - Direct Ownership
  S - Sell AS - Automatic Sell I - Indirect Ownership
  OE - Options Exercised A - Acquired
  IO - Initital Ownership D - Disposed
 
 
    Copyright © 2024 j3sg.com | Disclaimer & Terms of use          Products & Service  About Us  Contact Us